Dr. Ingmar Gorman on Psychedelic-Assisted Psychotherapy

The Psychedelic Entrepreneur - Medicine for These Times with Beth Weinstein

Dr. Ingmar Gorman is a Co-founder and Chief Executive Officer of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.

In this episode, Beth and Dr. Gorman discuss …

• Whether a psychedelic therapist needs to be licensed
• The lack of protective mechanisms for clients that seek psychedelic therapy from unlicensed people
• The power of being an integration support person
• Psilocybin as an effective treatment for multiple psychiatric “disorders”
• Spiritual bypassing in the psychedelic realm
• How healing happens in relationship - not in a self-help vacuum

Free Gifts!

• Research paper: Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
• Upcoming training: Psychedelic Integration: Premise and Promise, Winter 2022 | Online - Fluence